semaglutide injections in india Sun Pharma receives DCGI approval for generic injection Novo Nordisk Launches Ozempic in

Asia-Pacific : Rapid Growth and Innovation Asia-Pacific is rapidly emerging as a significant player in the glutathione market, holding approximately 20% of the global share

But the tremendous success of GLP-1s for weight loss has created a blind spot that has caused many to overlook the potential of microdosing GLP-1 for individuals with autoimmune or inflammatory conditions

Yoneyama K, Venkatesh BA, Wu CO, Mewton N, Gjesdal O, Kishi S, et al

At the same time, Novo is not resting on its success, as it explores the use of semaglutide for various other conditions, including metabolic dysfunction-associated steatohepatitis, heart failure, and even Alzheimers disease